Single-pill combination of telmisartan/Amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: An 8-week randomized, parallel-group, double-blind trial

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages 537-551

  Sharma, Arya M ^a   Bakris, George ^b   Neutel, Joel M ^c   Littlejohn, Thomas W ^d   Kobe, Maureen ^e   Ting, Naitee ^e   Ley, Ludwin ^f  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CHICAGO   (United States)

^c Orange County Research Center   (United States)

^d Piedmont Medical Research Associates   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Hypertension; Metabolic syndrome; Obesity; Single pill combination; Telmisartan amlodipine; Type 2 diabetes mellitus

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS TELMISARTAN;

ADULT; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTERIOSCLEROSIS; ARTICLE; BACKACHE; BODY MASS; BRONCHITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; JOINT SWELLING; LEG FRACTURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL EDEMA; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT WITHDRAWAL; ULCER;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84863421559     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.004     Document Type: Article

References (49)

1. Ezzati M., Oza S., Danaei G., Murray C.J. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008, 117:905-914.
2. Ostchega Y., Dillon C.F., Hughes J.P., et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007, 55:1056-1065.
3. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303:2043-2050.
4. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
5. Wolf-Maier K., Cooper R.S., Kramer H., et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10-17.
6. Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
7. Mancia G., Laurent S., Agabiti-Rosei E., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27:2121-2158.
8. Wang Y.R., Alexander G.C., Stafford R.S. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007, 167:141-147.
9. Falaschetti E., Chaudhury M., Mindell J., Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009, 53:480-486.
10. Kotseva K., Wood D., De Backer G., et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940. EUROASPIRE Study Group.
11. Antikainen R.L., Kastarinen M.J., Jousilahti P., et al. Despite evidence-based guidelines, systolic blood pressure remains inadequately controlled in older hypertensive adults. J Hum Hypertens 2010, 24:439-446.
12. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
13. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840. ADVANCE Collaborative Group.
14. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585. The ACCORD Study Group.
15. White W.B., Littlejohn T.W., Majul C.R., et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010, 15:205-212.
16. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559. ONTARGET Investigators.
17. Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population?. J Int Med Res 2009, 37:1662-1679.
18. Littlejohn T., Mroczek W., Marbury T., et al. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000, 16:1123-1132.
19. Sharma A.M., Hollander A., Köster J. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005, 63:250-257. Efficacy and Safety in Patients with Renal Impairment; treated with Telmisartan (ESPRIT) Study Group.
20. Yusuf S., Teo K., Anderson C., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174-1183.
21. Sharma A., Bagchi A., Kinagi S.B., et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007, 29:2667-2676.
22. Littlejohn T.W., Majul C.R., Olvera R., et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009, 11:207-213.
23. Littlejohn T.W., Majul C.R., Olvera R., et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med 2009, 121:5-14.
24. Guthrie R., Dahlöf B., Jamerson K., et al. Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients. Curr Med Res Opin 2011, 27:1995-2008.
25. Neutel J., Mancia G., Black H., et al. Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: TEAMSTA severe HTN study: HT.1.04. J Hypertens 2010, 28:e46.
26. Neldam S., Lang M., Jones R. Telmisartan and amlodipine single-pill combinations versus amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 Study. J Clin Hypertens 2011, 13:459-466. TEAMSTA-5 Investigators.
27. Neldam S., Lang M. Fixed-dose combination therapy with telmisartan and amlodipine 5 mg in non-responders to amlodipine 5 mg provides superior blood pressure reductions to, and is better tolerated than, amlodipine 10 mg. J Clin Hypertens 2009, 11(Suppl A):A129.
28. Oigman W., Neves M.F., Gismondi R.A. Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results. Expert Rev Cardiovasc Ther 2010, 8:1509-1517.
29. Mallinckrod C.H., Lane P.W., Schnell D., et al. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information J 2008, 42:303-319.
30. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031. VALUE trial group.
31. Weber M.A., Julius S., Kjeldsen S.E., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049-2051.
32. Dahlöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906. ASCOT Investigators.
33. Cooper-DeHoff R.M., Egelund E.F., Pepine C.J. Blood pressure lowering in patients with diabetes-one level might not fit all. Nat Rev Cardiol 2011, 8:42-49.
34. Denardo S.J., Messerli F.H., Gaxiola E., et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol 2010, 106:498-503.
35. Tomlinson J.W., Owen K.R., Close C.F. Treating hypertension in diabetic nephropathy. Diabetes Care 2003, 26:1802-1805.
36. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428. ACCOMPLISH Trial Investigators.
37. Jamerson K.A., Devereux R., Bakris G.L., et al. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 2011, 57:174-179.
38. Nissen S.E., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004, 292:2217-2226.
39. Pitt B., Byington R.P., Furberg C.D., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000, 102:1503-1510.
40. Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients (CHIEF) trial Accessed February 27, 2012. http://clinicaltrials.gov/ct2/show/NCT01011660.
41. Peti-Peterdi J., Toma I., Vargas S.L., Koo J. P648: improved renal hemodynamics in diabetic rats treated with Telmisartan and Amlodipine. Eur Heart J 2010, 31(Abstract Suppl):88.
42. Bakris G., Sarifidis P., Weir M., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173-1181. ACCOMPLISH Trial Investigators.
43. Parati G., Faini A., Valentini M. Blood pressure variability: its measurement and significance in hypertension. Curr Hypertens Rep 2006, 8:199-204.
44. Schumacher H., Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008, 1:32-40.
45. Kreutz R. Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag 2011, 7:183-192.
46. Kostis J.B. Antihypertensive therapy with CCB/ARB combination in older individuals: focus on amlodipine/valsartan combination. Am J Ther 2010, 17:188-196.
47. Makani H., Bangalore S., Romero J., et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011, 124:128-135.
48. Frishman W.H., Ram C.V., McMahon F.G., et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995, 35:1060-1066.
49. McGill J.B. Improving microvascular outcomes in patients with diabetes through management of hypertension. Postgrad Med 2009, 121:89-101.